Related Experiment Video
Updated: Feb 15, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies
John F Deeken1, Hongkun Wang2, Marion Hartley2
1Inova Schar Cancer Institute, Inova Health System, 3300 Gallows Road, Falls Church, VA, 22042, USA. john.deeken@inova.org.
Purpose:
The artemisinin class of anti-malarial drugs has shown significant anti-cancer activity in pre-clinical models. Proposed anti-cancer mechanisms include DNA damage, inhibition of angiogenesis, TRAIL-mediated apoptosis, and inhibition of signaling pathways. We performed a phase I study to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of intravenous artesunate (IV AS).
Methods:
Patients were enrolled in an accelerated titration dose escalation study with planned dose levels of 8, 12, 18, 25, 34 and 45 mg/kg given on days 1 and 8 of a 21-day cycle. Toxicities were assessed using the NCI CTCAE (ver. 4.0), and response was assessed using RECIST criteria (version 1.1). Pharmacokinetic (PK) studies were performed during cycle 1.
Results:
A total of 19 pts were enrolled, 18 of whom were evaluable for toxicity and 15 were evaluable for efficacy. DLTs were seen at dosages of 12 (1 of 6 patients), 18 (1 of 6) and 25 mg/kg (2 of 2), and were neutropenic fever (Gr 4), hypersensitivity reaction (Gr 3), liver function test abnormalities (Gr 3/4) along with neutropenic fever, and nausea/vomiting (Gr 3) despite supportive care. The MTD was determined to be 18 mg/kg. No responses were observed, while four patients had stable disease, including three with prolonged stable disease for 8, 10, and 11 cycles, for a disease control rate of 27%. PK parameters of AS and its active metabolite, dihydroartemisinin (DHA), correlated with dose.
Conclusion:
The MTD of intravenous artesunate is 18 mg/kg on this schedule. Treatment was well tolerated. Modest clinical activity was seen in this pre-treated population. CLINICALTRIALS.
Gov Identifier:
NCT02353026.
Insights
Intravenous artesunate (IV AS) showed a maximum tolerated dose of 18 mg/kg in a Phase I study. While no complete responses were observed, the drug demonstrated modest clinical activity and was well tolerated in pre-treated patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Artemisinin derivatives exhibit anti-cancer properties in preclinical models.
- Potential mechanisms include DNA damage, anti-angiogenesis, and apoptosis induction.
Purpose of the Study:
- To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of intravenous artesunate (IV AS).
Main Methods:
- Phase I, accelerated titration dose escalation study.
- Dose levels ranged from 8 to 45 mg/kg given on days 1 and 8 of a 21-day cycle.
- Toxicity assessed by NCI CTCAE (ver. 4.0), response by RECIST (v1.1), and pharmacokinetics (PK) during cycle 1.
Main Results:
- 19 patients enrolled; 18 evaluable for toxicity, 15 for efficacy.
- MTD established at 18 mg/kg, with DLTs including neutropenic fever and liver function abnormalities.
- 27% disease control rate observed, with three patients achieving prolonged stable disease.
Conclusions:
- The MTD for IV AS is 18 mg/kg on the studied schedule.
- IV AS was well tolerated and showed modest clinical activity in a heavily pre-treated population.
- Further investigation in Phase II trials may be warranted.
Related Concept Videos
Phase Diagrams
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Phase Transitions
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...

